{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:20:43Z","timestamp":1794277243661,"version":"4.9.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82403895"],"award-info":[{"award-number":["82403895"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82303799"],"award-info":[{"award-number":["82303799"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Excellent Young Talent Research Start-up Fund from the Fifth Affiliated Hospital of Sun Yat-sen University","award":["KY2024040006"],"award-info":[{"award-number":["KY2024040006"]}]},{"name":"the Zhuhai Social Development Science and Technology Plan Project","award":["2420004000280"],"award-info":[{"award-number":["2420004000280"]}]},{"name":"the Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0529300"],"award-info":[{"award-number":["2024ZD0529300"]}]},{"name":"the Science and Technology Development Fund of the Macao SAR","award":["0004\/2021\/AKP"],"award-info":[{"award-number":["0004\/2021\/AKP"]}]},{"name":"the Talent-Attracting Fund from the Fifth Affiliated Hospital of Sun Yat-sen University","award":["220904094208"],"award-info":[{"award-number":["220904094208"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Chimeric antigen receptor T (CAR-T) cell therapy faces critical barriers in solid tumors, including poor infiltration, T cell exhaustion, and immunosuppressive microenvironments, resulting in response rates below 10%. Herein, we engineered an inhalable nanoplatform using induced pluripotent stem cell-derived exosomes (IEXOs) displaying bispecific PD-1\/mesothelin (MSLN) single-chain variable fragments (scFv) and loaded with indole-3-propionic acid (IPA) for metabolic reprogramming. IEXOs demonstrated high yield and intrinsic antitumor properties, inhibiting Lewis lung carcinoma (LLC) cell proliferation and migration. The bispecific exosomes loaded with IPA (BIEXO@IPA) achieved efficient pulmonary delivery\n                    <jats:italic>via<\/jats:italic>\n                    nebulization with 79.3% tumor cell-specific uptake versus 47.9% for liposomes in orthotopic lung cancer models. BIEXO@IPA treatment reduced tumor burden by 87.9% and achieved 80% survival at 80 days. Mechanistically, BIEXO@IPA bridged PD-1\n                    <jats:sup>+<\/jats:sup>\n                    T cells to MSLN\n                    <jats:sup>+<\/jats:sup>\n                    tumor cells through bispecific engagement while expanding progenitor exhausted T (Tpex) cells and reducing regulatory T cells. When combined with CAR-T cells, BIEXO@IPA achieved 66.7% complete remission with 100% survival at 80 days and 83.3% resistance to tumor rechallenge. Safety assessments revealed minimal toxicity. This BIEXO@IPA platform represents a scalable, clinically translatable strategy that addresses fundamental CAR-T limitations in solid tumors through synergistic multimodal immunomodulation.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1186\/s12951-026-04242-3","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:35:44Z","timestamp":1773747344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Engineering BiTE-inspired IPSC-exosomes to potentiate CAR-T cell therapy against lung cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Ronghao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guining","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haozhao","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanglin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwen","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiasheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianchuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingdong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"4242_CR1","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, Diaz-Beya M, Juan M, Urbano-Ispizua \u00c1, Esteve J, Velasco-Hernandez T, Men\u00e9ndez P. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Therapy. 2025;10:210.","journal-title":"Signal Transduct Target Therapy"},{"key":"4242_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00694-6","volume":"12","author":"J Yang","year":"2022","unstructured":"Yang J, He J, Zhang X, Li J, Wang Z, Zhang Y, et al. Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study. Blood Cancer J. 2022;12:104.","journal-title":"Blood Cancer J"},{"key":"4242_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"4242_CR4","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","volume":"42","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Chen J, Andreatta M, Feng B, Xie Y-Q, Wenes M, et al. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat Biotechnol. 2024;42:1693\u2013704.","journal-title":"Nat Biotechnol"},{"key":"4242_CR5","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/cancers15030663","volume":"15","author":"YJ Chen","year":"2023","unstructured":"Chen YJ, Abila B, Mostafa Kamel Y. CAR-T: what is next? Cancers (Basel). 2023;15:663. https:\/\/doi.org\/10.3390\/cancers15030663.","journal-title":"Cancers (Basel)"},{"key":"4242_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3425291","volume":"2019","author":"B Hou","year":"2019","unstructured":"Hou B, Tang Y, Li W, Zeng Q, Chang D. Efficiency of CAR-T therapy for treatment of solid tumor in clinical trials: a meta-analysis. Dis Markers. 2019;2019:3425291.","journal-title":"Dis Markers"},{"key":"4242_CR7","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","volume":"20","author":"SS Kachala","year":"2014","unstructured":"Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K, et al. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin Cancer Res. 2014;20:1020\u20138.","journal-title":"Clin Cancer Res"},{"key":"4242_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","volume":"43","author":"B Du","year":"2025","unstructured":"Du B, Qin J, Lin B, Zhang J, Li D, Liu M. CAR-T therapy in solid tumors. Cancer Cell. 2025;43:665\u201379.","journal-title":"Cancer Cell"},{"key":"4242_CR9","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.ccell.2018.04.001","volume":"33","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell. 2018;33:853-861.e854.","journal-title":"Cancer Cell"},{"key":"4242_CR10","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24:1550\u20138.","journal-title":"Nat Med"},{"key":"4242_CR11","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.ccell.2022.06.001","volume":"40","author":"JA Belk","year":"2022","unstructured":"Belk JA, Yao W, Ly N, Freitas KA, Chen YT, Shi Q, et al. Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. Cancer Cell. 2022;40:768-786.e767.","journal-title":"Cancer Cell"},{"key":"4242_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51978-3","volume":"15","author":"CM Stewart","year":"2024","unstructured":"Stewart CM, Siegler EL, Sakemura RL, Cox MJ, Huynh T, Kimball B, et al. IL-4 drives exhaustion of CD8\u2009+\u2009CART cells. Nat Commun. 2024;15:7921.","journal-title":"Nat Commun"},{"key":"4242_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/cancers13020210","volume":"13","author":"M Haist","year":"2021","unstructured":"Haist M, Stege H, Grabbe S, Bros M. The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment. Cancers (Basel). 2021;13:210. https:\/\/doi.org\/10.3390\/cancers13020210.","journal-title":"Cancers (Basel)"},{"key":"4242_CR14","doi-asserted-by":"publisher","first-page":"8579","DOI":"10.1021\/acsnano.4c14102","volume":"19","author":"X Xu","year":"2025","unstructured":"Xu X, Wang X, Liao Y-P, Luo L, Nel AE. Reprogramming the tolerogenic immune response against pancreatic cancer metastases by lipid nanoparticles delivering a STING agonist plus mutant KRAS mRNA. ACS Nano. 2025;19:8579\u201394.","journal-title":"ACS Nano"},{"key":"4242_CR15","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli PS, Zauderer MG, Rivi\u00e8re I, Solomon SB, Rusch VW, O\u2019Cearbhaill RE, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 2021;11:2748\u201363.","journal-title":"Cancer Discov"},{"key":"4242_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111339","volume":"137","author":"JE Zhou","year":"2021","unstructured":"Zhou JE, Yu J, Wang Y, Wang H, Wang J, Wang Y, et al. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft. Biomed Pharmacother. 2021;137:111339.","journal-title":"Biomed Pharmacother"},{"key":"4242_CR17","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","volume":"37","author":"BD Choi","year":"2019","unstructured":"Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019;37:1049\u201358.","journal-title":"Nat Biotechnol"},{"key":"4242_CR18","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ymthe.2022.05.011","volume":"30","author":"Y Yin","year":"2022","unstructured":"Yin Y, Rodriguez JL, Li N, Thokala R, Nasrallah MP, Hu L, et al. Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors. Mol Ther. 2022;30:2537\u201353.","journal-title":"Mol Ther"},{"key":"4242_CR19","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/icb.2014.93","volume":"93","author":"AM Huehls","year":"2015","unstructured":"Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 2015;93:290\u20136.","journal-title":"Immunol Cell Biol"},{"key":"4242_CR20","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.2967\/jnumed.120.259036","volume":"62","author":"FV Suurs","year":"2021","unstructured":"Suurs FV, Lorenczewski G, Bailis JM, Stienen S, Friedrich M, Lee F, et al. Mesothelin\/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues. J Nucl Med. 2021;62:1797\u2013804.","journal-title":"J Nucl Med"},{"key":"4242_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","volume":"402","author":"N van de Donk","year":"2023","unstructured":"van de Donk N, Zweegman S. T-cell-engaging bispecific antibodies in cancer. Lancet. 2023;402:142\u201358.","journal-title":"Lancet"},{"key":"4242_CR22","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","volume":"17","author":"M-E Goebeler","year":"2020","unstructured":"Goebeler M-E, Bargou RC. T cell-engaging therapies \u2014 BiTEs and beyond. Nat Rev Clin Oncol. 2020;17:418\u201334.","journal-title":"Nat Rev Clin Oncol"},{"key":"4242_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01067-5","volume":"14","author":"J Edeline","year":"2021","unstructured":"Edeline J, Houot R, Marabelle A, Alcantara M. CAR-T cells and BiTEs in solid tumors: challenges and perspectives. J Hematol Oncol. 2021;14:65.","journal-title":"J Hematol Oncol"},{"key":"4242_CR24","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41590-020-0760-z","volume":"21","author":"DT Utzschneider","year":"2020","unstructured":"Utzschneider DT, Gabriel SS, Chisanga D, Gloury R, Gubser PM, Vasanthakumar A, Shi W, Kallies A. Early precursor T cells establish and propagate T cell exhaustion in chronic infection. Nat Immunol. 2020;21:1256\u201366.","journal-title":"Nat Immunol"},{"key":"4242_CR25","first-page":"499","volume":"21","author":"Z Fang","year":"2024","unstructured":"Fang Z, Ding X, Huang H, Jiang H, Jiang J, Zheng X. Revolutionizing tumor immunotherapy: unleashing the power of progenitor exhausted T cells. Cancer Biol Med. 2024;21:499\u2013512.","journal-title":"Cancer Biol Med"},{"key":"4242_CR26","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.cell.2024.02.022","volume":"187","author":"D Jia","year":"2024","unstructured":"Jia D, Wang Q, Qi Y, Jiang Y, He J, Lin Y, et al. Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer. Cell. 2024;187:1651-1665.e1621.","journal-title":"Cell"},{"key":"4242_CR27","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.chom.2024.03.011","volume":"32","author":"Z Pi","year":"2024","unstructured":"Pi Z, Liu W, Mao W. One size might fit all: Indole-3-propionic acid potentiates pan-cancer immunotherapy. Cell Host Microbe. 2024;32:627\u201330.","journal-title":"Cell Host Microbe"},{"key":"4242_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.coi.2012.01.010","volume":"24","author":"MP Chao","year":"2012","unstructured":"Chao MP, Weissman IL, Majeti R. The CD47-SIRP\u03b1 pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol. 2012;24:225\u201332.","journal-title":"Curr Opin Immunol"},{"key":"4242_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102291","volume":"53","author":"Y Luan","year":"2025","unstructured":"Luan Y, Zhang Y, Li S, Gao C, Ying X, Zhao S, et al. CD47 is a tumor cell-derived exosomal signature and regulates tumor immune microenvironment and immunotherapy responses. Transl Oncol. 2025;53:102291.","journal-title":"Transl Oncol"},{"key":"4242_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201801899","volume":"6","author":"Q Zhu","year":"2019","unstructured":"Zhu Q, Ling X, Yang Y, Zhang J, Li Q, Niu X, et al. Embryonic stem cells-derived exosomes endowed with targeting properties as chemotherapeutics delivery vehicles for glioblastoma therapy. Adv Sci. 2019;6:1801899.","journal-title":"Adv Sci"},{"key":"4242_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202101110","volume":"33","author":"J Hong","year":"2021","unstructured":"Hong J, Kang M, Jung M, Lee YY, Cho Y, Kim C, et al. T-cell-derived nanovesicles for cancer immunotherapy. Adv Mater. 2021;33:e2101110.","journal-title":"Adv Mater"},{"key":"4242_CR32","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1089\/ten.teb.2019.0252","volume":"26","author":"R Jeske","year":"2020","unstructured":"Jeske R, Bejoy J, Marzano M, Li Y. Human pluripotent stem cell-derived extracellular vesicles: characteristics and applications. Tissue Eng Part B Rev. 2020;26:129\u201344.","journal-title":"Tissue Eng Part B Rev"},{"key":"4242_CR33","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/s41587-024-02386-x","volume":"43","author":"J Gu","year":"2025","unstructured":"Gu J, Iyer A, Wesley B, Taglialatela A, Leuzzi G, Hangai S, et al. Mapping multimodal phenotypes to perturbations in cells and tissue with CRISPRmap. Nat Biotechnol. 2025;43:1101\u201315.","journal-title":"Nat Biotechnol"},{"key":"4242_CR34","doi-asserted-by":"publisher","first-page":"E11111","DOI":"10.1073\/pnas.1708991114","volume":"114","author":"MT Zhao","year":"2017","unstructured":"Zhao MT, Chen H, Liu Q, Shao NY, Sayed N, Wo HT, et al. Molecular and functional resemblance of differentiated cells derived from isogenic human iPSCs and SCNT-derived ESCs. Proc Natl Acad Sci U S A. 2017;114:E11111-e11120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4242_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01809-0","volume":"9","author":"J Cerneckis","year":"2024","unstructured":"Cerneckis J, Cai H, Shi Y. Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications. Signal Transduct Target Ther. 2024;9:112.","journal-title":"Signal Transduct Target Ther"},{"key":"4242_CR36","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.jmb.2015.09.019","volume":"428","author":"S Keerthikumar","year":"2016","unstructured":"Keerthikumar S, Chisanga D, Ariyaratne D, Al Saffar H, Anand S, Zhao K, et al. ExoCarta: a web-based compendium of exosomal cargo. J Mol Biol. 2016;428:688\u201392.","journal-title":"J Mol Biol"},{"key":"4242_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01704-0","volume":"9","author":"F Tan","year":"2024","unstructured":"Tan F, Li X, Wang Z, Li J, Shahzad K, Zheng J. Clinical applications of stem cell-derived exosomes. Signal Transduct Target Ther. 2024;9:17.","journal-title":"Signal Transduct Target Ther"},{"key":"4242_CR38","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ymthe.2019.11.020","volume":"28","author":"X Shi","year":"2020","unstructured":"Shi X, Cheng Q, Hou T, Han M, Smbatyan G, Lang JE, et al. Genetically engineered cell-derived nanoparticles for targeted breast cancer immunotherapy. Mol Ther. 2020;28:536\u201347.","journal-title":"Mol Ther"},{"key":"4242_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01382-y","volume":"8","author":"M Zhang","year":"2023","unstructured":"Zhang M, Hu S, Liu L, Dang P, Liu Y, Sun Z, et al. Engineered exosomes from different sources for cancer-targeted therapy. Signal Transduct Target Ther. 2023;8:124.","journal-title":"Signal Transduct Target Ther"},{"key":"4242_CR40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s12276-023-01132-8","volume":"56","author":"I Jung","year":"2024","unstructured":"Jung I, Shin S, Baek MC, Yea K. Modification of immune cell-derived exosomes for enhanced cancer immunotherapy: current advances and therapeutic applications. Exp Mol Med. 2024;56:19\u201331.","journal-title":"Exp Mol Med"},{"key":"4242_CR41","doi-asserted-by":"publisher","first-page":"9355","DOI":"10.2147\/IJN.S281890","volume":"15","author":"J Shao","year":"2020","unstructured":"Shao J, Zaro J, Shen Y. Advances in exosome-based drug delivery and tumor targeting: from tissue distribution to intracellular fate. Int J Nanomed. 2020;15:9355\u201371.","journal-title":"Int J Nanomed"},{"key":"4242_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02414-7","volume":"22","author":"J Jiang","year":"2024","unstructured":"Jiang J, Lu Y, Chu J, Zhang X, Xu C, Liu S, et al. Anti-EGFR ScFv functionalized exosomes delivering LPCAT1 specific siRNAs for inhibition of lung cancer brain metastases. J Nanobiotechnology. 2024;22:159.","journal-title":"J Nanobiotechnology"},{"key":"4242_CR43","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1016\/j.ymthe.2022.06.013","volume":"30","author":"Q Cheng","year":"2022","unstructured":"Cheng Q, Dai Z, Smbatyan G, Epstein AL, Lenz HJ, Zhang Y. Eliciting anti-cancer immunity by genetically engineered multifunctional exosomes. Mol Ther. 2022;30:3066\u201377.","journal-title":"Mol Ther"},{"key":"4242_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12085","volume":"10","author":"M Kang","year":"2021","unstructured":"Kang M, Jordan V, Blenkiron C, Chamley LW. Biodistribution of extracellular vesicles following administration into animals: a systematic review. J Extracell Vesicles. 2021;10:e12085.","journal-title":"J Extracell Vesicles"},{"key":"4242_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12134","volume":"10","author":"MM Shi","year":"2021","unstructured":"Shi MM, Yang QY, Monsel A, Yan JY, Dai CX, Zhao JY, et al. Preclinical efficacy and clinical safety of clinical-grade nebulized allogenic adipose mesenchymal stromal cells-derived extracellular vesicles. J Extracell Vesicles. 2021;10:e12134.","journal-title":"J Extracell Vesicles"},{"key":"4242_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101847","volume":"6","author":"M Hirayama","year":"2025","unstructured":"Hirayama M, Hatou S, Nomura M, Hokama R, Hirayama OI, Inagaki E, et al. A first-in-human clinical study of an allogenic iPSC-derived corneal endothelial cell substitute transplantation for bullous keratopathy. Cell Rep Med. 2025;6:101847.","journal-title":"Cell Rep Med"},{"key":"4242_CR47","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.stem.2024.12.005","volume":"32","author":"A Kirkeby","year":"2025","unstructured":"Kirkeby A, Main H, Carpenter M. Pluripotent stem-cell-derived therapies in clinical trial: a 2025 update. Cell Stem Cell. 2025;32:10\u201337.","journal-title":"Cell Stem Cell"},{"key":"4242_CR48","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"JS Suk","year":"2016","unstructured":"Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99:28\u201351.","journal-title":"Adv Drug Deliv Rev"},{"key":"4242_CR49","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/adma.201201800","volume":"24","author":"LM Ensign","year":"2012","unstructured":"Ensign LM, Schneider C, Suk JS, Cone R, Hanes J. Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery. Adv Mater. 2012;24:3887\u201394.","journal-title":"Adv Mater"},{"key":"4242_CR50","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","volume":"177","author":"M Poggio","year":"2019","unstructured":"Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 2019;177:414-427.e413.","journal-title":"Cell"},{"key":"4242_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02390-y","volume":"24","author":"L Shui","year":"2025","unstructured":"Shui L, Wu D, Yang K, Sun C, Li Q, Yin R. Bispecific antibodies: unleashing a new era in oncology treatment. Mol Cancer. 2025;24:212.","journal-title":"Mol Cancer"},{"key":"4242_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55751-4","volume":"16","author":"T Zhu","year":"2025","unstructured":"Zhu T, Xiao Y, Chen Z, Ding H, Chen S, Jiang G, et al. Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung. Nat Commun. 2025;16:262.","journal-title":"Nat Commun"},{"key":"4242_CR53","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41565-023-01580-3","volume":"19","author":"M Liu","year":"2024","unstructured":"Liu M, Hu S, Yan N, Popowski KD, Cheng K. Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity. Nat Nanotechnol. 2024;19:565\u201375.","journal-title":"Nat Nanotechnol"},{"key":"4242_CR54","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1021\/acsnano.4c13053","volume":"19","author":"K Huang","year":"2025","unstructured":"Huang K, Liu Y, Miao H, Li Y, Fan Q, Zhang H, et al. Nebulized lipid nanoparticles based on degradable ionizable glycerolipid for potent pulmonary mRNA delivery. ACS Nano. 2025;19:1128\u201339.","journal-title":"ACS Nano"},{"key":"4242_CR55","doi-asserted-by":"publisher","first-page":"24204","DOI":"10.1021\/acsnano.4c05653","volume":"18","author":"M Jang","year":"2024","unstructured":"Jang M, Yeom K, Han J, Fagan E, Park J-H. Inhalable mRNA nanoparticle with enhanced nebulization stability and pulmonary microenvironment infiltration. ACS Nano. 2024;18:24204\u201318.","journal-title":"ACS Nano"},{"key":"4242_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2024.154170","volume":"496","author":"R Wang","year":"2024","unstructured":"Wang R, Li X, Fu G, Hu M, Dou H, Zhang G, et al. Hybrid nanovesicles comprising induced pluripotent stem cells and dendritic cell-derived exosomes enhance antitumor immunity. Chem Eng J. 2024;496:154170.","journal-title":"Chem Eng J"},{"key":"4242_CR57","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.ymthe.2023.06.005","volume":"31","author":"R Wang","year":"2023","unstructured":"Wang R, Zhu T, Hou B, Huang X. An iPSC-derived exosome-pulsed dendritic cell vaccine boosts antitumor immunity in melanoma. Mol Ther. 2023;31:2376\u201390.","journal-title":"Mol Ther"},{"key":"4242_CR58","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","volume":"18","author":"Z Wang","year":"2021","unstructured":"Wang Z, Li N, Feng K, Chen M, Zhang Y, Liu Y, et al. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell Mol Immunol. 2021;18:2188\u201398.","journal-title":"Cell Mol Immunol"},{"key":"4242_CR59","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1158\/1535-7163.MCT-17-1138","volume":"17","author":"W Leconet","year":"2018","unstructured":"Leconet W, Liu H, Guo M, Le Lamer-D\u00e9champs S, Molinier C, Kim S, et al. Anti-PSMA\/CD3 bispecific antibody delivery and antitumor activity using a polymeric depot formulation. Mol Cancer Ther. 2018;17:1927\u201340.","journal-title":"Mol Cancer Ther"},{"key":"4242_CR60","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature22341","volume":"546","author":"S Kamerkar","year":"2017","unstructured":"Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, Lee JJ, Kalluri R. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017;546:498\u2013503.","journal-title":"Nature"},{"key":"4242_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24384-2","volume":"12","author":"M Mathieu","year":"2021","unstructured":"Mathieu M, N\u00e9vo N, Jouve M, Valenzuela JI, Maurin M, Verweij FJ, et al. Specificities of exosome versus small ectosome secretion revealed by live intracellular tracking of CD63 and CD9. Nat Commun. 2021;12:4389.","journal-title":"Nat Commun"},{"key":"4242_CR62","first-page":"903","volume":"22","author":"X Mei","year":"2023","unstructured":"Mei X, Li J, Wang Z, Zhu D, Huang K, Hu S, Popowski KD, Cheng K. An inhaled bioadhesive hydrogel to shield non-human primates from SARS-CoV-2 infection. Nat Mater. 2023;22:903\u201312.","journal-title":"Nat Mater"},{"key":"4242_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202211138","volume":"35","author":"X Li","year":"2023","unstructured":"Li X, Zhu T, Wang R, Chen J, Tang L, Huo W, et al. Genetically programmable vesicles for enhancing CAR-T therapy against solid tumors. Adv Mater. 2023;35:e2211138.","journal-title":"Adv Mater"},{"key":"4242_CR64","doi-asserted-by":"publisher","first-page":"11626","DOI":"10.1021\/acsnano.3c02075","volume":"17","author":"C Liu","year":"2023","unstructured":"Liu C, Xi L, Liu Y, Mak JCW, Mao S, Wang Z, et al. An inhalable hybrid biomimetic nanoplatform for sequential drug release and remodeling lung immune homeostasis in acute lung injury treatment. ACS Nano. 2023;17:11626\u201344.","journal-title":"ACS Nano"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04242-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04242-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04242-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T03:43:42Z","timestamp":1777002222000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04242-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4242"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04242-3","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted following the ARRIVE guidelines and were approved by the Animal Ethics Committee of the Fifth Affiliated Hospital of Sun Yat-sen University (approval number: 00560).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"388"}}